TD Cowen Forecasts Strong Price Appreciation for Revvity (NYSE:RVTY) Stock

Key Points

• TD Cowen raised its price target on Revvity to $120 and maintains a "buy" rating, implying about a 20.6% upside from the prior close.
• Revvity beat Q1 expectations with $1.06 EPS (vs. $1.02 est.) and $711.1M revenue, sending shares up roughly 7.8% to $99.50 intraday.
• Management's FY‑2026 guidance of $5.20–$5.30 EPS and softer revenue targets fell below Street estimates, prompting mixed analyst responses and leaving a consensus rating of Hold with a $107.36 average price target.

Revvity (NYSE:RVTY - Get Free Report) had its target price upped by equities research analysts at TD Cowen from $115.00 to $120.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. TD Cowen's price target indicates a potential upside of 20.61% from the company's previous close.

A number of other analysts have also issued reports on the stock. Jefferies Financial Group increased their price target on shares of Revvity from $100.00 to $105.00 and gave the stock a "hold" rating in a research report on Monday, February 2nd. Evercore increased their price target on shares of Revvity from $112.00 to $118.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 3rd. The Goldman Sachs Group reduced their price target on shares of Revvity from $110.00 to $95.00 and set a "neutral" rating for the company in a research report on Tuesday, April 14th. Wall Street Zen lowered shares of Revvity from a "buy" rating to a "hold" rating in a research report on Saturday, April 18th. Finally, Stifel Nicolaus reduced their price target on shares of Revvity from $110.00 to $100.00 and set a "hold" rating for the company in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $107.36.

Revvity Trading Up 7.8%

Shares of RVTY traded up $7.20 during midday trading on Wednesday, hitting $99.50. The stock had a trading volume of 1,857,997 shares, compared to its average volume of 1,278,166. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $118.30. The business has a 50-day simple moving average of $90.23 and a two-hundred day simple moving average of $96.82. The firm has a market cap of $11.12 billion, a P/E ratio of 47.84, a price-to-earnings-growth ratio of 1.84 and a beta of 1.05. The company has a current ratio of 1.68, a quick ratio of 1.40 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The company had revenue of $711.12 million during the quarter, compared to analysts' expectations of $704.07 million. During the same period last year, the company posted $1.01 earnings per share. The business's revenue for the quarter was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, equities analysts forecast that Revvity will post 5.39 EPS for the current year.

Hedge Funds Weigh In On Revvity

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RVTY. AQR Capital Management LLC raised its position in Revvity by 5.2% during the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company's stock valued at $883,000 after acquiring an additional 420 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Revvity by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company's stock valued at $1,246,000 after acquiring an additional 744 shares in the last quarter. Millennium Management LLC raised its position in Revvity by 102.0% during the first quarter. Millennium Management LLC now owns 69,401 shares of the company's stock valued at $7,343,000 after acquiring an additional 35,048 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Revvity by 45.5% during the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company's stock valued at $64,232,000 after acquiring an additional 189,871 shares in the last quarter. Finally, Focus Partners Wealth raised its position in shares of Revvity by 13.0% in the first quarter. Focus Partners Wealth now owns 7,028 shares of the company's stock valued at $744,000 after purchasing an additional 811 shares during the period. Institutional investors own 86.65% of the company's stock.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 results beat expectations — Revvity reported $1.06 EPS (vs. ~$1.02 est.) and $711.1M revenue (vs. ~$704M est.), with revenue up ~7% year-over-year, which drove the immediate bullish reaction. Article Title
• Positive Sentiment: Underlying organic growth and execution — management cited ~3% organic growth and portfolio execution that helped offset margin pressure; commentary on strategic moves (including plans around China ImmunoDx) framed the beat as operationally driven. Article Title
• Neutral Sentiment: Full earnings materials and call available — the company published the earnings press release, slide deck and the Q1 earnings-call transcript for investors to review management’s details on demand drivers and cost dynamics. Slide Deck / Press Release
• Negative Sentiment: FY‑2026 guidance came in light — management set EPS guidance of $5.20–$5.30 (below consensus ~$5.40) and provided revenue guidance around $2.8B (below the ~$3.0B Street estimate), which could cap upside if execution or end‑market trends weaken. Article Title
• Negative Sentiment: Analyst reactions — at least one shop (Robert W. Baird) cut its price target and consensus broker ratings sit around “Hold,” reflecting some caution from sell‑side firms after the softer guide. Article Title

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.